Medgenome Logo
Prima Logo
SPIT SEQ - Whole Genome Sequencing of MTb (Mycobacterium Tuberculosis) for Pulmonary Tuberculosis
Lung image

Request for a call back

Name field is not valid
Email field is not valid
Mobile field is not valid
City field is not valid

Thank you for reaching out to us. We will contact you soon.

Prevalence of Tuberculosis in India

Worldwide, TB is one of the top 10 causes of death, and the leading cause from a single infectious agent (above HIV / AIDS). According to a WHO report, India saw 2.7

million TB cases (incidence + relapse) in 2017. India accounted for 27% of global TB deaths. Globally, 3.5% of new TB cases and 18% of previously treated cases had multi-drug resistant/rifampicin resistant TB (MDR/RR-TB). India is one of the top 3 countries with the largest number of MDR/RR-TB cases that constitute 47% of global MDR/RR-TB cases.

Why choose MedGenome?

MedGenome's whole genome sequencing of MTB covers all drug resistance markers and can also be used for strain typing, epidemiology studies and disease surveillance.

  • A single test application covers both diagnosis and drug resistance.
  • Provides strain typing
  • Direct sputum specimen requirement
  • Resistance testing for all drugs in a single sequencing cycle
  • Covers novel drug resistance mutation coverage
  • Quick turn around time of just 15 days
  • Achieves 100% sensitivity compared to Line Probe Assay
  • Accomplishes 98.04% specificity compared to Line Probe Assay

Test details

MedGenome Genomic MTB Test
Test Code RS062
TAT 15 working days
Sample Specimen Sterile container- To be transported within 24 hours in cold condition
Additional Requirements Duly filled TRF with available TB test reports
Call 1800 103 3691
www.medgenome.com | diagnostics@medgenome.com